Our partnerships with the pharmaceutical industry
Our partnerships with pharmaceutical companies allow us to deliver vital work supporting people affected by blood cancer.
The support we received in FY25 is detailed below.
Unless otherwise stated, these companies played no part in the organisation, design, or content of any of the work listed.
For more information on how and why we work with the industry, read our Policy on working with pharma.
Our 2025 report
£45,910 worth of funding was directed towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients. A further £20,000 for our direct referral service and £5,000 to sponsor our Blood Cancer Awareness Month health information packs.
£45,910 worth of funding went towards Blood Cancer Action Plan, a national report to identify and make meaningful and realistic recommendations for change to improve survival of blood cancer patients.
£35,000 worth of funding went towards our direct referral service and £325 in speaker consultancy fees.
£50,000 worth of funding went towards our direct referral service.
£10,000 worth of funding went towards our Clinical Trials Support Service and £10,000 towards our CNS Programme of Support.
£15,000 worth of funding went towards our direct referral service.
£30,000 worth of funding went towards our Clinical Trials Support Service.
£5,000 worth of funding went towards our direct referral service.
£15,000 worth of funding went towards our direct referral service.
£10,000 worth of funding went towards our direct referral service, £5,000 towards our CNS Programme of Support and £428 in speaker consultancy fees.
£17,200 worth of funding went towards an infection health information project.
£30,000 worth of funding went towards our Clinical Trials Support Service, £1,350 in CEO consultancy fees, £2,600 consultancy for the patient charter project and £64.50 travel expenses for a meeting.
£10,000 worth of funding went towards our direct referral service and £314 in speaker consultancy fees.
£20,000 worth of funding went towards our Clinical Trials Support Service.
£5,000 worth of funding went towards speaker consultancy fees.
£10,000 worth of funding went towards our CNS Programme of Support.
£15,000 worth of funding went towards our Clinical Trials Support Service.
£15,000 worth of funding went towards our CNS Programme of Support and £951 for party conference costs.
Get in touch with the Corporate Partnerships Team
Get in touch